证据不支持来那度胺与CCI-779通过P-糖蛋白发生具有临床意义的相互作用。 - Suppr

Suppr

超能文献

Evidence does not support clinically significant lenalidomide-CCI-779 interaction via P-glycoprotein.

作者信息

Chen Nianhang, Kasserra Claudia, Kumar Gondi, Palmisano Maria

出版信息

J Clin Oncol. 2012 Jan 20;30(3):340-1; author reply 341-2. doi: 10.1200/JCO.2011.39.4163. Epub 2011 Dec 12.

DOI:10.1200/JCO.2011.39.4163

PMID:22162571

Abstract

摘要

相似文献

Evidence does not support clinically significant lenalidomide-CCI-779 interaction via P-glycoprotein.

J Clin Oncol. 2012 Jan 20;30(3):340-1; author reply 341-2. doi: 10.1200/JCO.2011.39.4163. Epub 2011 Dec 12.

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.

J Clin Oncol. 2011 Sep 1;29(25):3427-34. doi: 10.1200/JCO.2010.32.4962. Epub 2011 Aug 8.

Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.

Eur J Cancer. 2011 Apr;47(6):814-8. doi: 10.1016/j.ejca.2010.12.026. Epub 2011 Feb 18.

Lenalidomide in multiple myeloma: current role and future directions.

Expert Opin Pharmacother. 2010 Apr;11(5):829-42. doi: 10.1517/14656561003645611.

Advances in treatment for relapses and refractory multiple myeloma.

Med Oncol. 2010 Jun;27 Suppl 1:S25-42. doi: 10.1007/s12032-009-9407-5. Epub 2010 Mar 6.

Panobinostat for the treatment of multiple myeloma.

Lancet Oncol. 2014 Oct;15(11):1178-9. doi: 10.1016/S1470-2045(14)70443-7. Epub 2014 Sep 18.

Histone deacetylase inhibitors in multiple myeloma.

Lancet Oncol. 2013 Oct;14(11):1038-1039. doi: 10.1016/S1470-2045(13)70425-X. Epub 2013 Sep 19.

Novel agents for relapsed and/or refractory multiple myeloma.

Cancer J. 2009 Nov-Dec;15(6):485-93. doi: 10.1097/PPO.0b013e3181c51cba.

The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines.

JAMA Oncol. 2016 Nov 1;2(11):1405-1406. doi: 10.1001/jamaoncol.2016.1782.

Panobinostat to revert bortezomib resistance.

Blood. 2013 Oct 3;122(14):2292-3. doi: 10.1182/blood-2013-08-522417.

引用本文的文献

No clinically significant drug interactions between lenalidomide and P‑glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers.

Cancer Chemother Pharmacol. 2014 May;73(5):1031-9. doi: 10.1007/s00280-014-2438-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Evidence does not support clinically significant lenalidomide-CCI-779 interaction via P-glycoprotein.

作者信息

Chen Nianhang, Kasserra Claudia, Kumar Gondi, Palmisano Maria

出版信息

J Clin Oncol. 2012 Jan 20;30(3):340-1; author reply 341-2. doi: 10.1200/JCO.2011.39.4163. Epub 2011 Dec 12.

DOI:10.1200/JCO.2011.39.4163

PMID:22162571

Abstract

摘要

相似文献

Evidence does not support clinically significant lenalidomide-CCI-779 interaction via P-glycoprotein.

J Clin Oncol. 2012 Jan 20;30(3):340-1; author reply 341-2. doi: 10.1200/JCO.2011.39.4163. Epub 2011 Dec 12.

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.

J Clin Oncol. 2011 Sep 1;29(25):3427-34. doi: 10.1200/JCO.2010.32.4962. Epub 2011 Aug 8.

Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.

Eur J Cancer. 2011 Apr;47(6):814-8. doi: 10.1016/j.ejca.2010.12.026. Epub 2011 Feb 18.

Lenalidomide in multiple myeloma: current role and future directions.

Expert Opin Pharmacother. 2010 Apr;11(5):829-42. doi: 10.1517/14656561003645611.

Advances in treatment for relapses and refractory multiple myeloma.

Med Oncol. 2010 Jun;27 Suppl 1:S25-42. doi: 10.1007/s12032-009-9407-5. Epub 2010 Mar 6.

Panobinostat for the treatment of multiple myeloma.

Lancet Oncol. 2014 Oct;15(11):1178-9. doi: 10.1016/S1470-2045(14)70443-7. Epub 2014 Sep 18.

Histone deacetylase inhibitors in multiple myeloma.

Lancet Oncol. 2013 Oct;14(11):1038-1039. doi: 10.1016/S1470-2045(13)70425-X. Epub 2013 Sep 19.

Novel agents for relapsed and/or refractory multiple myeloma.

Cancer J. 2009 Nov-Dec;15(6):485-93. doi: 10.1097/PPO.0b013e3181c51cba.

The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines.

JAMA Oncol. 2016 Nov 1;2(11):1405-1406. doi: 10.1001/jamaoncol.2016.1782.

Panobinostat to revert bortezomib resistance.

Blood. 2013 Oct 3;122(14):2292-3. doi: 10.1182/blood-2013-08-522417.

引用本文的文献

No clinically significant drug interactions between lenalidomide and P‑glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers.

Cancer Chemother Pharmacol. 2014 May;73(5):1031-9. doi: 10.1007/s00280-014-2438-4.